- Home
- CRAI vs EWTX Comparison
CRAI vs EWTX Comparison
Compare CRAI & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRAI
- EWTX
- Stock Information
- Founded
- CRAI 1965
- EWTX 2017
- Country
- CRAI United States
- EWTX United States
- Employees
- CRAI N/A
- EWTX N/A
- Industry
- CRAI Other Consumer Services
- EWTX Biotechnology: Pharmaceutical Preparations
- Sector
- CRAI Consumer Discretionary
- EWTX Health Care
- Exchange
- CRAI Nasdaq
- EWTX Nasdaq
- Market Cap
- CRAI 1.2B
- EWTX 1.5B
- IPO Year
- CRAI 1998
- EWTX 2021
- Fundamental
- Price
- CRAI $197.15
- EWTX $14.85
- Analyst Decision
- CRAI Buy
- EWTX Buy
- Analyst Count
- CRAI 1
- EWTX 9
- Target Price
- CRAI $228.00
- EWTX $39.89
- AVG Volume (30 Days)
- CRAI 80.3K
- EWTX 654.8K
- Earning Date
- CRAI 07-31-2025
- EWTX 08-07-2025
- Dividend Yield
- CRAI 1.02%
- EWTX N/A
- EPS Growth
- CRAI 44.21
- EWTX N/A
- EPS
- CRAI 8.27
- EWTX N/A
- Revenue
- CRAI $712,913,000.00
- EWTX N/A
- Revenue This Year
- CRAI $7.47
- EWTX N/A
- Revenue Next Year
- CRAI $4.48
- EWTX N/A
- P/E Ratio
- CRAI $23.85
- EWTX N/A
- Revenue Growth
- CRAI 9.28
- EWTX N/A
- 52 Week Low
- CRAI $152.57
- EWTX $10.60
- 52 Week High
- CRAI $214.01
- EWTX $38.12
- Technical
- Relative Strength Index (RSI)
- CRAI 63.32
- EWTX 62.16
- Support Level
- CRAI $183.75
- EWTX $13.53
- Resistance Level
- CRAI $193.68
- EWTX $14.49
- Average True Range (ATR)
- CRAI 6.09
- EWTX 0.67
- MACD
- CRAI 1.28
- EWTX 0.14
- Stochastic Oscillator
- CRAI 83.91
- EWTX 88.54
About CRAI CRA International Inc.
CRA International Inc is a U.S.-based advisory firm that provides economic, financial, and management consultancy services. The company advises clients on economic and financial issues relating to litigation and regulatory proceedings and helps businesses set important business strategies and solve performance-related issues. The company's clients include domestic and foreign companies, government agencies, public and private utilities, and national and international trade associations. CRA International generates majority of its revenue from the United States, while it also has its presence in United Kingdom and Other Countries.
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.